As the United States stock market enters 2025, major indices like the Dow Jones and S&P 500 are attempting to recover from a sluggish start, following a challenging end to 2024. In such conditions, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for investors looking to capitalize on market inefficiencies.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Clear Secure (NYSE:YOU) | $27.04 | $53.41 | 49.4% |
Argan (NYSE:AGX) | $143.32 | $279.51 | 48.7% |
Burke & Herbert Financial Services (NasdaqCM:BHRB) | $60.50 | $118.65 | 49% |
German American Bancorp (NasdaqGS:GABC) | $38.85 | $77.34 | 49.8% |
Camden National (NasdaqGS:CAC) | $42.25 | $84.44 | 50% |
Cadence Bank (NYSE:CADE) | $33.70 | $65.46 | 48.5% |
Kanzhun (NasdaqGS:BZ) | $13.64 | $26.99 | 49.5% |
HealthEquity (NasdaqGS:HQY) | $96.81 | $189.22 | 48.8% |
Repligen (NasdaqGS:RGEN) | $143.05 | $281.09 | 49.1% |
Zillow Group (NasdaqGS:ZG) | $70.08 | $137.46 | 49% |
Click here to see the full list of 175 stocks from our Undervalued US Stocks Based On Cash Flows screener.
We'll examine a selection from our screener results.
Overview: ChromaDex Corporation is a bioscience company that develops healthy aging products and has a market cap of approximately $406.10 million.
Operations: The company's revenue is derived from three primary segments: Ingredients ($16.95 million), Consumer Products ($71.72 million), and Analytical Reference Standards and Services ($3.00 million).
Estimated Discount To Fair Value: 35.1%
ChromaDex is trading at US$5.48, below its estimated fair value of US$8.44, suggesting it may be undervalued based on cash flows. The company recently reported a profitable quarter with net income of US$1.88 million, a turnaround from the previous year's loss. Its earnings are forecasted to grow significantly at 81.8% annually, outpacing the broader U.S. market growth rate of 14.9%. Recent product rollouts and partnerships further bolster revenue prospects.
Overview: Inspire Medical Systems, Inc. is a medical technology company that develops and commercializes minimally invasive solutions for obstructive sleep apnea, with a market cap of approximately $5.56 billion.
Operations: The company generates revenue primarily from its Patient Monitoring Equipment segment, totaling $755.59 million.
Estimated Discount To Fair Value: 16.8%
Inspire Medical Systems, trading at US$189.19, is undervalued with a fair value estimate of US$227.52. The company reported significant financial turnaround with Q3 net income of US$18.5 million against a prior loss and raised its 2024 revenue guidance to US$793-798 million, reflecting growth over the previous year. Revenue is forecasted to grow faster than the U.S. market at 15.2% annually, while earnings are expected to increase significantly by 31.3% per year.
Overview: Rush Street Interactive, Inc. operates as an online casino and sports betting company across the United States, Canada, Mexico, and Latin America with a market cap of approximately $3.10 billion.
Operations: The company's revenue is primarily generated from its Casinos & Resorts segment, which amounts to $863.77 million.
Estimated Discount To Fair Value: 28.3%
Rush Street Interactive is trading at US$13.74, below its estimated fair value of US$19.16, indicating it may be undervalued based on cash flows. The company reported Q3 sales of US$232.11 million and achieved a net income turnaround to US$1.19 million from a loss last year. With revenue expected to grow 32% year-over-year in 2024, RSI's strategic moves, including launching BetRivers Poker and board expansion with Thomas Winter, bolster its growth potential.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:CDXC NYSE:INSP and NYSE:RSI.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.